James Paul Rickey, Chief Financial Officer, on August 05, 2026, executed a purchase for 27,777 shares in Braveheart Bio (BRVE) for $499,986. Following the Form 4 filing with the SEC, Rickey has control over a total of 703,575 common shares of the company, with 520,927 shares held directly and 182,648 controlled indirectly.
SEC Filing: